Breaking News

BARDA, ICON Partner to Execute Next-Gen COVID Vaccine Trial

ICON will execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine.

ICON plc., a healthcare intelligence and clinical research organization, is partnering with the U.S. Biomedical Advanced Research and Development Authority (BARDA), to execute a clinical trial to evaluate the effectiveness of next generation COVID-19 vaccine candidates. The trial is part of Project NextGen, which coordinates across the U.S. Government and the private sector to advance innovative vaccines and therapeutics into clinical trials, regulatory review, and potential commercial availa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters